Sail’s CEO, Guillaume Pfefer, will be speaking on an esteemed panel at the 𝗝𝗣 𝗠𝗼𝗿𝗴𝗮𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟱 to discuss 𝙢𝙍𝙉𝘼 𝙏𝙝𝙚𝙧𝙖𝙥𝙞𝙚𝙨: 𝘼𝙙𝙫𝙖𝙣𝙘𝙞𝙣𝙜 𝙖𝙣𝙙 𝙎𝙘𝙖𝙡𝙞𝙣𝙜 𝙩𝙝𝙚 𝙁𝙪𝙩𝙪𝙧𝙚 𝙤𝙛 𝙈𝙚𝙙𝙞𝙘𝙞𝙣𝙚. If you are attending #JPM25, join us on Tuesday, January 14 at 9 am PT. This dynamic discussion will delve into the efficacy and commercial viability of mRNA and targeted neo-antigen therapies, addressing key challenges in manufacturability, scalability, delivery, redosing, and cost of goods (COGs). Panel Moderators: Ipsita Smolinski, Capitol Street Ariel Kantor, PhD, ReCode Therapeutics Featured Panelists: Joe Payne, CEO, Arcturus Therapeutics Gilles Besin, CSO, Orbital Therapeutics Sadik Kassim, CSO, Danaher Corporation (Genomic Medicines) Guillaume Pfefer, CEO, Sail Biomedicines Visit our updated website to learn more about Sail Biomedicines: https://www.sail.bio/ #JPM2025 #JPMHC25 #JPMWeek #BioWeekSF #mRNA #RNA #programmablemedicines
Sail Biomedicines
Biotechnology Research
Cambridge, Massachusetts 4,351 followers
Generating tomorrow's medicines today through the language of life
About us
We work at the frontier of programmable medicines. We power our bioplatform and product candidates by harnessing evolution and AI. We operate with purpose and urgency on behalf of people everywhere. We aim to generate life-changing impact for the world.
- Website
-
https://www.sail.bio/
External link for Sail Biomedicines
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
Locations
-
Primary
Get directions
140 1st St
Cambridge, Massachusetts 02141, US
Employees at Sail Biomedicines
Updates
-
Nature, machines, and human creativity combined—a new era of #polyintelligence. At Sail, this approach underpins how we are generating life-changing #RNA medicines. Read Noubar Afeyan’s annual letter for Flagship Pioneering to explore this transformative vision: https://lnkd.in/gMXqie4J #JPM25 #FlagshipFounded #FlagshipJPM #AI
Read or listen to Flagship Pioneering’s 2025 Annual Letter in which Founder & CEO Noubar Afeyan explores polyintelligence — the synthesis of human, machine, and nature's intelligence, and how it is driving a new renaissance in science and technology: bit.ly/Polyintelligence Drawing inspiration from Leonardo da Vinci's integrated thinking, Noubar discusses how artificial intelligence will enhance our understanding of nature's adaptive genius in unprecedented ways. He highlights breakthroughs in biotechnology, agriculture, and machine intelligence, and how these polyintelligent innovations can tackle multifaceted challenges in health, climate, and beyond. And for more on how polyintelligence is informing and guiding Flagship’s work, dive into our newly launched Special Section: bit.ly/FlagshipPolyintell #BiggerLeaps #FlagshipStudio #JPM25
-
Rajesh Ramaswamy, SVP, Head of Machine Learning and Artificial Intelligence Strategy at Sail Biomedicines will be in the Flagship Pioneering Studio at #JPM25 discussing #𝗔𝗜 𝗶𝗻 𝗔𝗰𝘁𝗶𝗼𝗻. This livestreamed panel will delve into the AI innovations driving breakthroughs in #drugdiscovery and design, and how AI is proving to be a core value driver to make leaps in human health. Learn more and register for the livestream, visit: https://lnkd.in/eKXF-e_Y #JPM2025 #JPMHC25 #JPMWeek #BioWeekSF #mRNA #RNA #programmablemedicines #FlagshipJPM #FlagshipFounded
-
-
Check out this great Advancing RNA article by Anna Rose Welch! She discusses the progress made in 2024 in the #RNA and #LNP space with thought leaders including Sail's CEO, Guillaume Pfefer #eRNA #endlessRNA
To be clear: No seances occurred during any of the executive interviews I carried out for my 2025 RNA industry outlook series. 👻 But as the title of my latest article should indicate, I did find myself channeling the spirit of Charles Dickens' A Christmas Carol. This year, I had five lively conversations with 6 (living) executives: CureVac's Alexander Zehnder, MD, MBA, Beam Therapeutics' Gopi Shanker, Nuntius Therapeutics Benita Nagel & Albert Kwok; Sail Biomedicines' Guillaume Pfefer; and NanoVation Therapeutics™' Dominik Witzigmann, PhD. Though we covered a lot of different topics, I singled out a few of their thoughts on the progress the encoding RNA/LNP spaces made in the past year and where we currently stand as we prepare to step into the new year ahead. A huge thanks to the army of people it took to get all of these interviews arranged and on the calendar, and, of course, to these six leaders for spending an hour with me this fall. Check it out and stay tuned for part 2!
-
And that's a wrap! The Sail team collaborated with the Caring for Children (Frank and Rosemary Iovieno Caring for Children Foundation) again this year to donate and wrap gifts and clothes for children living with life-threatening or life-limiting illnesses. We're proud to participate in this fantastic initiative and help spread some joy this holiday season.
-
-
Sail's Chief Platform Officer, Kerry Benenato, will participate in the "State of the Industry" panel at the Alliance for mRNA Medicines' first Annual Meeting this afternoon - we're looking forward to a great event!
-
-
Our Chief Platform Officer, Kerry Benenato, will present at Partnership Opportunities in Drug Development, where she'll discuss Sail’s innovative technology platforms and pipeline of programmable RNA medicines. See the agenda for #PODD2024 from The Conference Forum: https://lnkd.in/g3xC9bta #eRNA #RNA #AI #machinelearning #GenAI #generativeAI #DrugDevelopment #DrugDelivery #geneticmedicines
-
-
A potential cystic fibrosis therapy with higher efficacy and a less-frequent dosing regimen than other mRNA approaches? We're excited to share promising preclinical data that suggest that Sail’s Endless RNA™ (eRNA™) may offer a new type of treatment for those with cystic fibrosis, including those for whom existing therapies are not an option. The Pioneering Medicines initiative of Flagship Pioneering will present a poster at #NAFC2024 on the effects of lab treatment with CFTR endless RNA on respiratory cells. Learn more about the Cystic Fibrosis Foundation funded research: https://lnkd.in/gJXtMsjz #eRNA #RNA #endlessRNA #CF #cysticfibrosis
-
-
Our CEO Guillaume Pfefer will present at Chardan’s 8th Annual Genetic Medicines Conference, where he'll discuss Sail’s latest advancements from our technology platforms to unlock the future of #geneticmedicine today with #endlessRNA. Request info about the conference from Chardan here: https://lnkd.in/gchdEUBH #ChardanGMConf #eRNA #RNA #AI #machinelearning #GenAI #generativeAI
-
-
Great interview with our CEO Guillaume Pfefer that covers a lot of topics – from his career journey to Sail’s comprehensive approach to creating new #geneticmedicines. With a stack of platform technologies, enabled by #AI and #machinelearning, Sail is engineering “performance by design” into new #RNA medicines to do better and more for patients. Read more at Informa: https://lnkd.in/gyWxfQAp #eRNA #endlessRNA #GenAI #generativeAI #AIinBiotech
-